US Pharma MarketingAbbVie
FDA approves AbbVie Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals:…
The FDA approved AbbVie’s next-generation therapy for Parkinson’s disease, tavapadon, a dopamine agonist that's expected to provide the symptom relief of its predecessors but with fewer side effects.
Tavapadon will be branded as Juvmo and ...
Source: Endpoints News